Skip to main content
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. — Investor Relations & Filings

Ticker · GOSS ISIN · US38341P1021 LEI · 549300ZOC0N2W6PSFR58 US Manufacturing
Filings indexed 424 across all filing types
Latest filing 2023-05-09 Regulatory Filings
Country US United States of America
Listing US GOSS

About Gossamer Bio, Inc.

https://www.gossamerbio.com/

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of its lead investigational product, seralutinib. The company is developing this therapy for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is an inhaled inhibitor of PDGFRα/β, CSF1R, and c-KIT, designed for delivery via a dry powder inhaler. The company's goal is to address the needs of patients with these rare diseases.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2023-05-09 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-09 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-05-05 English
ARS
Annual Report
2023-04-28 English
DEFA14A
Regulatory Filings
2023-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.